The system can lock its payload in place and control how it is released
A new injectable material designed to deliver drug therapies and sensor technology to targeted areas within the human body is being developed by a Texas A&M University biomedical engineer who says the system can lock its payload in place and control how it is released.
The research, led by Michael McShane, professor in the Department of Biomedical Engineering who specializes in biomaterials, and graduate student Jason Roberts, appears in “Journal of Materials Chemistry B.” It details the development of a carrier system embedded with microscopic capsules that act as tiny reservoirs for medicines or even sensors that would alert a person in critical instances, such as when blood-sugar levels change.
The technology, McShane notes, affords researchers a high degree of control over what is delivered to the body, where and when it is delivered and how much of it is delivered. That degree of flexibility, he says, could make the system an extremely useful tool when it comes to targeted drug delivery.
As opposed to having patients simply swallow a pill, health care professionals have long envisioned delivering specific quantities of medicines to targeted areas of the body, thereby increasing the treatment’s effectiveness while reducing side effects. In order to achieve this, a “vehicle” of sorts is needed to safely and accurately deliver the medicine to the desired location within the body.
McShane’s team, which also includes graduate student Dustin Ritter, is building that vehicle using a modified Jell-O-like substance known as a hydrogel. A hydrogel is a polymer mesh material that is typically biocompatible, meaning it allows cells within the body to conduct normal physiological processes without triggering an immune response from the host. Because of this, hydrogels are widely used in tissue engineering research, and they can be found in a number of other applications, most commonly as the material from which contact lenses are made.
Although hydrogels aren’t new, the ones employed in McShane’s carrier system aren’t typical; they’ve been enhanced. Specifically, they are embedded with tiny capsules that are significantly smaller than the width of a human hair. Each of these microcapsules serves as a reservoir or depot for the material doctors and researchers want to deliver, such as a drug.
Measuring a few microns in diameter, these porous microparticles are made from clusters of calcium carbonate nanoparticles that have been deliberately formed around a specific material to trap it inside, McShane notes. Once the desired material is trapped within the microsphere, multiple layers of polymers are wrapped around the particles, he explains. This allows for a precise and customizable control over how the microcapsule will release its contents when it interacts with its surrounding environment, McShane explains.
The system, McShane says, is not limited to drug delivery. In fact, it has shown promising results with biosensors. In these types of applications, he explains, the microcapsules carry a payload, such as a protein, that is responsive to something in the body that doctors want to measure. This measurable material is allowed to pass into the hydrogel and into the capsules where it triggers some type of optical change, he says. For example, McShane has been able to trigger a color change in the material (observable with a reader device) when pH and oxygen levels change or when blood-sugar levels fluctuate. It’s work that could translate into safer and more effective ways for people, such as those suffering from diabetes, to monitor their conditions.
The Latest on: Targeted drug delivery
via Google News
The Latest on: Targeted drug delivery
- Italy blocks export of AstraZeneca coronavirus vaccine to Australia, amid EU anger over delivery shortfallson March 4, 2021 at 3:48 am
Italy has blocked the export to Australia of 250,000 AstraZeneca coronavirus vaccine doses, amid a dispute with the drug manufacturer over delivery shortfalls inside the European Union, the Italian ...
- Global Biologic Drug Product Contract Manufacturer Quality Benchmarking Study 2021on March 2, 2021 at 4:33 am
The "Biologic Drug Product Contract Manufacturer Quality Benchmarking (4th Edition)" report has been added to ResearchAndMarkets.com's offering. This Biologic Drug Product Contract Manufacturing ...
- Targeted drug delivery system more effective to treat cancer cells Scientists News Todayon February 26, 2021 at 1:04 am
Chennai: Glioblastoma multiforme (also called glioblastoma) is the most common and aggressive form of primary brain tumour and it's the most common type of malignant brain tumour among adults. Now ...
- Former Lititz pharmacist convicted of drug charges to settle related federal case for $2.9 millionon February 26, 2021 at 12:00 am
A former Lititz pharmacist who for years illegally sold opioid and anti-anxiety drugs without prescriptions will pay $2.9 million to settle a federal civil case.
- Fabrication of anionic dextran-coated micelles for aptamer targeted delivery of camptothecin and survivin-shRNA to colon adenocarcinomaon February 25, 2021 at 7:01 am
In this study, we synthesized PLA-PEI micelles which was co-loaded with an anticancer drug, camptothecin (CPT), and survivin-shRNA (sur-shRNA). The hydrophobic CPT was encapsulated in the core of the ...
- Brain targeted system for delivery of highly toxic anti-cancer drugon February 25, 2021 at 4:08 am
Targeted delivery of anti-cancer drug to a localised tumor site has shown to improve the effectiveness of treatment as it concentrates drug at their site of action, and thus reducing side effects at ...
- Targeted delivery of highly toxic anti-cancer drug to brain tumorson February 23, 2021 at 10:56 am
University of Houston biomedical researcher Sheeren Majd is reporting the development and testing of a new nano-carrier as a potential treatment to deliver highly toxic medicine to glioblastomas, the ...
- Eyeing oral Humira, Progenity takes delivery vehicle into clinicon February 23, 2021 at 5:02 am
Progenity has begun a phase 1 clinical trial of its ingestible and self-guided drug delivery device. The study will assess the device’s gastrointestinal tolerability and ability to deliver a payload ...
- Noveome Biotherapeutics, Inc. To Present At The 9th Annual Virtual Neurodegenerative Drug Development Summiton February 22, 2021 at 6:31 am
Noveome Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged ...
- Global Targeted Drug Delivery System Market Overview, Development Factors and Growth Analysis 2021-2026on February 17, 2021 at 10:18 pm
Global "Targeted Drug Delivery System Market" report provides key analysis on the market status of Targeted Drug Delivery System manufacturers with the best facts and figures, definitions ...
via Bing News